A Phase 2 interventional study of Fexofenadine and Placebo - Cap in Gastroesophageal Reflux, sponsored by Stanford University. Terminated at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2021-02-17.
Sponsored by Stanford University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 421 studies in Gastroesophageal Reflux with a site in United States — 55 open to participants now, 70 under way, 2 of them phase 3. Gastroesophageal Reflux · United States.
Among the 421 studies in Gastroesophageal Reflux with a site in United States, this one is the 259th largest by enrollment of the 302 interventional ones that give a count, is one of 11 that started in 2018, is one of 35 in phase 2, and was the 316th registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
Browse Gastroesophageal Reflux studies →55 of the 421 studies in Gastroesophageal Reflux with a site in United States are open now. Recruiting first, the newest first:
Abbott Medical Devices · Sites in United States
Ages 18+
Phathom Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 21+
Medical College of Wisconsin · Sites in United States
Ages 18+ · Healthy volunteers
Abbott Medical Devices · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
421 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 45 · Phase 3 47 · Phase 4 34
First in 1999; this study’s year is marked. 11 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 60 across the 302 interventional studies, 90 across the 116 observational. Of the 304 that completed or were terminated, 116 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 421 have an industry lead sponsor. The 10 most frequent:
Stanford University is the lead sponsor of 2,169 studies on the registry; 431 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 207 (78%) have results posted.
Stanford University has 5 studies filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
26 of the studies in Gastroesophageal Reflux with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07752407Phase 3Phathom Pharmaceuticals, Inc.A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks | 2027-10-20 |
| NCT01696734Phase 3M.D. Anderson Cancer CenterDomperidone in Treating Patients With Gastrointestinal Disorders | 2027-10-31 |
| NCT04506593Indiana UniversityIndiana University Gastrointestinal Motility Diagnosis Registry | 2026-11 |
| NCT05697393Medical College of WisconsinExternal UES Band (Shaker Pressure Band) and GERD | 2026-11-30 |
| NCT03705416Johns Hopkins UniversityLong Term Outcomes of Bariatric Patients Treated With Surgery or Endoscopy | 2026-12 |
Add all 26 to your calendar (.ics) → With an account.
Among the 421 studies in Gastroesophageal Reflux with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators wish to study the effectiveness of Fexofenadine (an over the counter allergy pill) for the treatment of gastroesophageal reflux symptoms in patients who still have symptoms despite being on a proton pump inhibitor. The investigators will do this by giving participants both Fexofenadine (an H1 blocker) for 2 weeks and placebo (sugar pill) for 2 weeks. The participants will not know which drug they are getting at a particular time. This will help the investigators better assess the true effectiveness of Fexofenadine.
Around 18-28% of North American adults have gastroesophageal reflux symptoms once per week. Of those patients up to 60% may have an inadequate response to proton pump inhibitors and have persistent symptoms. One possible explanation is that this group of patients has nerve related pain. It is thought that H1 receptor activation may sensitize the gastrointestinal tract and esophagus to pain. H1 blockers such as anti-histamines may play a role in treatment of gastroesophageal reflux symptoms that are refractory to proton pump inhibitors by reducing pain perception. The investigators wish to conduct a randomized control trial to test this hypothesis. The investigators will do this by giving participants both Fexofenadine (an H1 blocker) for 2 weeks and placebo (sugar pill) for 2 weeks. The participants will not know which drug they are getting at a particular time. This will help the investigators better assess the true effectiveness of Fexofenadine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria (selected)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in this group will get 2 weeks of fexofenadine, then 1 week of nothing, then 2 weeks of placebo.
Drug: Fexofenadine · Drug: Placebo - Cap
Patients in this group will get 2 weeks of placebo, then 1 week of nothing, then 2 weeks of fexofenadine.
Drug: Fexofenadine · Drug: Placebo - Cap
Fexofenadine 180 mg in the morning
Placebo cap in the morning
Mean Percent of Days With Reflux
Time frame: 2 weeks per treatment
Mean Number of Reflux Episodes Per Day
Time frame: 2 weeks per treatment
Mean GERD-HRQL Questionnaire Score
The questionnaire consists of 10 questions with responses of 0-5. The responses of the 10 questions are totaled (range of 0-50) where a higher total indicates more severe disease than a lower total.
Time frame: 2 weeks per treatment
Mean Symptom Severity Score
Severity of reflux symptoms on a scale of 0-4 (0=none, 1=mild, 2=moderate, 3=severe, 4=very severe)
Time frame: 2 weeks per treatment
Mean Rescue Medications Per Day
Medications such as Tums or Pepcid can be used if reflux symptoms are severe and relief is needed (additional doses of proton pump inhibitors are not allowed beyond the regular dosing)
Time frame: 2 weeks per treatment
Patient Medication Preference
Patients will be asked which medication they think better helps treat their reflux symptoms, placebo or Fexofenadine.
Time frame: Will be assessed at the end of the trial (total trial time is 6 weeks)
Count of Participants With Side Effects
Patients will write down side effects at the end of each treatment period. If severe patients should seek medical attention immediately and report the side effects to us.
Time frame: Will be assessed at the end of the initial treatment period (2 weeks) and at the end of the crossover period (2 weeks)
| Milestone | Fexofenadine Then Placebo | Placebo Then Fexofenadine |
|---|---|---|
| Started | 6 | 5 |
| Completed | 6 | 5 |
| Not completed | 0 | 0 |
| Milestone | Fexofenadine Then Placebo | Placebo Then Fexofenadine |
|---|---|---|
| Started | 6 | 5 |
| Completed | 6 | 5 |
| Not completed | 0 | 0 |
| Milestone | Fexofenadine Then Placebo | Placebo Then Fexofenadine |
|---|---|---|
| Started | 6 | 5 |
| Completed | 6 | 5 |
| Not completed | 0 | 0 |
| percentage of days | Run-in Period | Fexofenadine | Placebo |
|---|---|---|---|
| Mean Percent of Days With Reflux | 83.4 (59.4 to 107.4) | 52.4 (4.3 to 100.4) | 52.4 (12.5 to 92.2) |
| episodes | Run-in Period | Fexofenadine | Placebo |
|---|---|---|---|
| Mean Number of Reflux Episodes Per Day | 1.74 (0.73 to 2.75) | 0.69 (-0.01 to 1.40) | 0.67 (-0.05 to 1.29) |
The questionnaire consists of 10 questions with responses of 0-5. The responses of the 10 questions are totaled (range of 0-50) where a higher total indicates more severe disease than a lower total.
| score on a scale | Run-in Period | Fexofenadine | Placebo |
|---|---|---|---|
| Mean GERD-HRQL Questionnaire Score | 16.2 (2.5 to 29.8) | 9.8 (-1.5 to 21.2) | 12.3 (4.0 to 20.7) |
Severity of reflux symptoms on a scale of 0-4 (0=none, 1=mild, 2=moderate, 3=severe, 4=very severe)
| score on a scale | Run-in Period | Fexofenadine | Placebo |
|---|---|---|---|
| Mean Symptom Severity Score | 1.2 (0.6 to 1.9) | 0.8 (-0.03 to 1.5) | 0.7 (-0.02 to 1.4) |
Medications such as Tums or Pepcid can be used if reflux symptoms are severe and relief is needed (additional doses of proton pump inhibitors are not allowed beyond the regular dosing)
| medications | Run-in Period | Fexofenadine | Placebo |
|---|---|---|---|
| Mean Rescue Medications Per Day | 0.29 (-0.31 to 0.89) | 0.52 (-0.75 to 1.80) | 0.17 (-0.14 to 0.47) |
Patients will be asked which medication they think better helps treat their reflux symptoms, placebo or Fexofenadine.
No measurements were reported for this outcome.
Patients will write down side effects at the end of each treatment period. If severe patients should seek medical attention immediately and report the side effects to us.
| Participants | Fexofenadine | Placebo |
|---|---|---|
| Count of Participants With Side Effects | 1 | 0 |
Collected over 6 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fexofenadine | 0/11 (0%) | 0/11 (0%) | 1/11 (9.1%) |
| Placebo | 0/11 (0%) | 0/11 (0%) | 0/11 (0%) |
| Event | Fexofenadine | Placebo |
|---|---|---|
| NosebleedRespiratory, thoracic and mediastinal disorders | 1/11 | 0/11 |
| Age, Customized(Participants) | All Participants |
|---|---|
| 40-49 years | 1 |
| 50-59 years | 1 |
| 60-69 years | 2 |
| 70-79 years | 1 |
| 80-89 years | 1 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 2 |
| Male | 7 |
| Ethnicity (NIH/OMB)(Participants) | All Participants |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 9 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | All Participants |
|---|---|
| United States | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2018 to primary completion in Jan 2019, 11 months.
Results were first posted in Feb 2021, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fexofenadine